Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski (Eli ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...

Eli Lilly (NYSE:LLY)'s newly FDA-approved obesity treatment, Mounjaro, also known as Zepbound, has spurred a 3.2% rise in the... Eli Lilly (NYSE:LLY) shares fell on Thursday after UnitedHealth ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Mounjaro and ... 8 billion in revenue. Eli Lilly and Co. shares climbed about 2% Thursday morning to $857.40 while broader trading indexes started the day mixed. Lilly's stock has already climbed ...